Heritage
| 1878 | Gisaburo Shiono, SR., founded the company Gisaburo Shiono, SR., founder of the company, started his career as a drug wholesaler at the present site of the head office, Doshomachi, Osaka |
|---|---|
| 1892 | Shionogi began manufacturing chemicals |
| 1897 | Shionogi started to deal directly with trading firms in Europe and the US Aspirin was first discovered in 1897 from a compound found in salicylate-bearing plants such as willow and poplar This gave rise to the hugely important class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs) |
| 1909 | Shionogi launched its first pharmaceutical product, Antacidin®, an antacid agent The Shionogi logo, the Fundoh, was registered as a company trademark The logo is called a Fundoh which is a copper weight used in Japanese scales. These weights played an important role in the development and dispensing of medicines. |
| 1928 | Penicillin, the most famous antibiotic, was discovered Penicillin discovered by Alexander Fleming at Saint Mary’s Medical School in London |
| 1929 | Adolf Butenandt and Edward Adelbert Doisy independently isolated the structure of oestrogen |
| 1943 | Two companies merged to create Shionogi & Co., Ltd. |
| 1957 | Shionogi established its first company mission “Shionogi strives constantly to supply the best possible medicine to protect the health and wellbeing of the patients we serve” |
| 1961 | The first formal Shionogi medical research laboratories were opened |
| 1963 | Shionogi expanded into Asia, opening an office in Taiwan |
| 1967 | Paclitaxel is a mitotic inhibitor used in cancer chemotherapy that was discovered within the bark of the Pacific yew tree in 1967 by US researchers Later it was found that endophytic fungi in the bark synthesize paclitaxel which is used to treat some patients with lung, ovarian, breast, head and neck cancer |
| 1970 | Shionogi launched in the US opening its first office in Los Angeles |
| 1978 | Shionogi celebrated its 100th anniversary |
| 1988 | Shionogi officially launched the Shionogi Institute for Medical Science |
| 1992 | Shionogi acquired the Eli Lilly subsidiary Qualicaps, which manufactures capsules, and started operations in the US |
| 2001 | Consolidated US operations and established Shionogi Inc. Established a joint venture named Shionogi- GlaxoSmithKline Pharmaceuticals LLC (later Shionogi- ViiV Healthcare LLC) The HIV integrase inhibitor dolutegravir was discovered and developed under Shionogi-GlaxoSmithKline Pharmaceuticals LLC |
| 2002 | Launched Claritin®, a second-generation histamine antagonist used to treat allergies |
| 2005 | Launched the hyperlipidemia treatment, Crestor®, which has been approved/marketed in over 100 countries and more than 19 million patients have been prescribed the drug worldwide Launched the carbapenem antibiotic, Finibax®, which has been approved for use in 87 countries across the world |
| 2007 | The Japanese initiative FINDS (PHarma-INnovation Discovery competition Shionogi) was founded This initiative would later become the Shionogi Science Program (SSP) Shionogi and Eli Lilly united to co-develop and co-market Cymbalta® for the treatment of a major depressive disorder and the management of diabetic peripheral neuropathic pain |
| 2008 | Established a joint research facility with Hokkaido University, Shionogi Innovation Centre for Drug Discovery Acquired Sciele Pharma, Inc. in the US under Shionogi Inc. Launched the acne vulgaris treatment, Differin® which has been approved /marketed in more than 80 countries, where it has become an important therapy for more than 22 million patients since its initial launch in France in 1995 |
| 2009 | Shionogi developed a joint venture known as Ezose Sciences Inc. which provides serum glycan analysis services Partnership with OncoTherapy Science, Inc (OTS), a biotech company was founded |
| 2010 | Launched Rapiacta®, an antiviral drug for influenza, which delivers high plasma concentrations to the sites of infection Launched Cymbalta® for the treatment of depression |
| 2011 | Shionogi Science Program was launched in the UK Opening of the Shionogi Pharmaceutical Research Centre in Osaka, Japan |
| 2012 | Shionogi launched European headquarters based in London Shionogi launched the injectable cancer pain analgesic, OxyFast®, an injectable formulation of oxycodone Oxyfast® developed following a request from the Japanese Society for Palliative Medicine to address the needs of some cancer patients who have difficulty using oral therapies The Shionogi Science Program is expanded to Australia, Belgium, Denmark, Luxembourg and Netherlands |
| 2013 | Shionogi Science Program launched in Germany and Ireland Ospemifene was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe dyspareunia Shionogi Europe opens affiliate office in Italy Shionogi Europe moves to new offices in Holborn, London |
| 2014 | Shionogi Europe opens affiliate office in Germany Shionogi Europe opens affiliate office in Spain New medium term business plan "SGS 2020" starts January 2014 ViiV Healthcare’s new HIV medicine Tivicay™ (dolutegravir) is approved in Europe September 2014 ViiV Healthcare’s new HIV medicine Triumeq™ (dolutegravir/ abacavir / lamivudine) is approved in Europe |
| 2015 | Shionogi receives Marketing Authorisation approval for Senshio (ospemifene) in EuropeShionogi receives Marketing Authorisation approval for Senshio (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women Shionogi begin to market Femal in ItalyA clinically tested dietary supplement to fight the typical symptoms of menopause such as hot flashes, night sweats, sleep disturbances, fatigue and irritability |
| 2016 | Shionogi Announces Availability of Senshio® (ospemifene) in SpainShionogi announces participation in The Cambridge Therapeutics ConsortiumShionogi announces it's participation in innovative new joint research initiative, The Cambridge Therapeutics Consortium. |